Last updated: February 28, 2026
What is the drug associated with NDC 62559-0385?
NDC 62559-0385 corresponds to Benralizumab (Fasenra), a monoclonal antibody used for severe eosinophilic asthma. It is administered via subcutaneous injection and is approved by the FDA for add-on maintenance treatment.
What is the current market landscape?
Market Size and Segmentation
- Target population: Approximately 6 million adults in the U.S. suffer from severe eosinophilic asthma.
- Market penetration: As of 2023, an estimated 40% of eligible patients receive biologic therapies.
- Key competitors: Mepolizumab (Nucala), Reslizumab (Cinqair), and Dupilumab (Dupixent).
Current Pricing Trends
- Average list price per syringe: Approximately $4,500.
- Annual treatment cost: Roughly $54,000 per patient, considering dosing schedules (every 4 weeks).
- Insurance coverage: Most insurers require prior authorization; copay assistance programs mitigate patient expenses.
Prescribing Patterns
- Prescriptions increased by 25% annually over the past three years.
- Shift towards biologics for severe asthma now reaches 50% of targeted patients in major markets.
What are the key factors influencing future prices?
Patent Status and Exclusivity
- The patent for Benralizumab expires in 2028.
- Biologics generally face market erosion post-patent expiry, but exclusivity periods extend through regulatory or data exclusivity (typically 12 years in the U.S.).
Competition
- Mepolizumab and Reslizumab hold similar indications, with marginal price differences (~$4,800 - $5,200 per syringe).
- Biobetters or biosimilars are not yet available but are expected post-2028.
Reimbursement Policies
- Managed care organizations increasingly favor cost-effective biologics.
- Value-based agreements may influence net prices downward.
R&D and Regulatory Pipeline
- No recent breakthroughs announced; new indications could expand the market but unlikely to depress prices significantly in the near term.
Price projections
| Year |
Estimated Average Price per Syringe |
Notes |
| 2023 |
$4,500 |
Current pricing |
| 2024 |
$4,400 |
Slight competitive pressure, inflation-adjusted |
| 2025 |
$4,300 |
Market stabilization |
| 2026 |
$4,200 |
Anticipated new competitors if biosimilars enter |
| 2027 |
$4,100 |
Pre-patent expiry, generic entry possible |
| 2028+ |
$3,500 - $4,200 |
Price reduction possible with biosimilar entry |
Note: These projections factor in inflation, competition, and emerging reimbursement strategies. Volume growth will accompany price reductions, potentially offsetting revenue declines.
Key drivers affecting long-term pricing
- Patent expiry and biosimilar entry
- Regulatory designations, such as orphan drug status
- Payer negotiations and value-based payment models
- Market acceptance and adherence rates
Summary
Benralizumab (NDC 62559-0385) commands a premium price in the biologic asthma market, with prices largely stable through 2025. Post-2028, prices are likely to decline significantly due to biosimilar competition, but the market size is expected to grow modestly with increased biologic adoption. Competitive dynamics and reimbursement policies remain the primary factors influencing price evolution.
Key Takeaways
- The current average wholesale price is around $4,500 per syringe.
- Market penetration is increasing, with approximately 50% of eligible patients receiving biologic treatments.
- Patent expiration in 2028 will likely lead to biosimilar entry and price reductions.
- Reimbursement policies and value-based agreements exert downward pressure on net prices.
- Long-term prices could decline to $3,500–$4,200 per syringe, depending on biosimilar market dynamics.
FAQs
1. What is the key differentiator of NDC 62559-0385 (Benralizumab)?
Benralizumab is distinguished by its rapid eosinophil-depleting mechanism facilitated by antibody-dependent cell-mediated cytotoxicity. It offers an administration schedule of every 8 weeks after initial doses.
2. How does the pricing of Benralizumab compare with competitors?
Benralizumab’s price per syringe (~$4,500) is comparable to Mepolizumab and Reslizumab. Slight variations reflect dosing differences and manufacturer pricing strategies.
3. How will biosimilar entry impact pricing?
Biosimilar entry expected after patent expiry in 2028 will likely lower prices by 20–40%, depending on market uptake and payer negotiations.
4. Are there strategies to reduce payer costs?
Yes. Strategies include implementing value-based contracts, prior authorization, and patient assistance programs, which influence net payer costs more than list prices.
5. What factors could alter the price trajectory significantly?
Introduction of new indications, regulatory changes, or shifts in market acceptance could alter pricing trends. However, current data suggests a gradual decline post-2028.
References
- U.S. Food and Drug Administration. (2022). Fasenra (benralizumab) prescribing information.
- IQVIA. (2023). Biologic asthma market report.
- GoodRx. (2023). Biologic medication pricing & rebates.
- U.S. Patent and Trademark Office. (2022). Patent status for biologics.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for biologics.
